Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Axcella Health Inc.AXLA · Entity 116059 | Chief Financial Officer | February 09, 2021 | February 11, 2021 |
| Prelude Therapeutics IncPRLD · Entity 5561 | Chief Financial Officer | March 01, 2024 | March 04, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Axcella Health Inc.
Report date February 09, 2021 · Filed February 11, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,266 |
Reported balance
After 2020-10-30 transaction · row 1
1 source rowRow 1 · 2020-10-30 · Grant · Acquired 2,601 · Balance 6,266 F1: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Axcella Health Inc. Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of May 1, 2020 to October 30, 2020. F2: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on October 30, 2020. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 60,000 |
Reported balance
After 2021-02-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-02-09 · Grant · Acquired 60,000 · Balance 60,000 F3: Each restricted stock unit ("RSU") represents a contingent right to receive one share of AXLA common stock. F4: The restricted stock units vest as follows: 1/3 of the grant shall vest on February 9, 2023 and the remaining 2/3 of the grant shall vest on February 9, 2024. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.59 · Expires 2031-02-08 | Direct | 120,000 |
Reported balance
After 2021-02-09 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-02-09 · Grant · Acquired 120,000 · Balance 120,000 F5: 25% of this option shall vest and become exercisable on February 9, 2022, with the remainder vesting in 12 equal quarterly installments thereafter. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.40 · Expires 2029-12-17 | Direct | 25,000 |
Reported balance
After 2021-02-09 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-02-09 · Grant · Acquired 25,000 · Balance 25,000 F6: On December 18, 2019, the reporting person was granted an option to purchase 25,000 shares of AXLA common stock, subject to the satisfaction of certain performance criteria. On February 9, 2021, the Issuer's Board of Directors confirmed that the performance criteria had been met. F7: This option shall vest and become exercisable in eight equal quarterly installments, with the first installment having vested on August 31, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Axcella Health Inc. Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of May 1, 2020 to October 30, 2020.
F2: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on October 30, 2020.
F3: Each restricted stock unit ("RSU") represents a contingent right to receive one share of AXLA common stock.
F4: The restricted stock units vest as follows: 1/3 of the grant shall vest on February 9, 2023 and the remaining 2/3 of the grant shall vest on February 9, 2024.
F5: 25% of this option shall vest and become exercisable on February 9, 2022, with the remainder vesting in 12 equal quarterly installments thereafter.
F6: On December 18, 2019, the reporting person was granted an option to purchase 25,000 shares of AXLA common stock, subject to the satisfaction of certain performance criteria. On February 9, 2021, the Issuer's Board of Directors confirmed that the performance criteria had been met.
F7: This option shall vest and become exercisable in eight equal quarterly installments, with the first installment having vested on August 31, 2020.
Prelude Therapeutics Inc
Report date March 01, 2024 · Filed March 04, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.59 · Expires 2034-02-28 | Direct | 150,000 |
Reported balance
After 2024-03-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-03-01 · Grant · Acquired 150,000 · Balance 150,000 F1: The stock option vests as to 25% of the total shares on March 1, 2025, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests as to 25% of the total shares on March 1, 2025, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 01, 2024 Filed Mar 4, 2024 18:04 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | GrantEmployee Stock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $4.59 | $0.00 |
DisclosureSEC source: 0001562180-24-002135 · primarydocument.xml · derivative · entry 1 Chardonnet Laurent · CIK 0001329010 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2034-02-28 F1 · derivative.exercise_date: The stock option vests as to 25% of the total shares on March 1, 2025, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| May 23, 2023 Filed May 25, 2023 16:05 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | PurchaseCommon Stock | 5,000 | $5.50 | $27,500.00 |
DisclosureSEC source: 0001562180-23-004477 · primarydocument.xml · nonDerivative · entry 1 Chardonnet Laurent · CIK 0001329010 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,165 F1 · balance_after: The reported total includes 1,292 shares of common stock the reporting person has acquired since the date of his last ownership report through the issuer's Employee Stock Purchase Plan in one or more transactions exempt pursuant to Rules 16b-3(c). Read SEC document |
| February 07, 2023 Filed Feb 9, 2023 16:07 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | GrantEmployee Stock Option (right to buy) · Derivative | 135,000 | $0.00 Strike: $7.20 | $0.00 |
DisclosureSEC source: 0001562180-23-001168 · primarydocument.xml · derivative · entry 1 Chardonnet Laurent · CIK 0001329010 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,000 Underlying: Common Stock · 135,000 shares Expires 2033-02-06 F1 · derivative.exercise_date: The stock option vests as to 25% of the total shares on February 7, 2024, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| December 21, 2022 Filed Dec 22, 2022 16:05 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | GrantEmployee Stock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $4.90 | $0.00 |
DisclosureSEC source: 0001562180-22-008416 · primarydocument.xml · derivative · entry 1 Chardonnet Laurent · CIK 0001329010 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2032-12-20 F1 · derivative.exercise_date: The stock option vests as to 25% of the total shares on December 21, 2023, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| December 08, 2022 Filed Dec 12, 2022 09:13 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | PurchaseCommon Stock | 10,000 | $4.76 | $47,600.00 |
DisclosureSEC source: 0001562180-22-008192 · primarydocument.xml · nonDerivative · entry 1 Chardonnet Laurent · CIK 0001329010 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,873 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.60 to $4.92, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F2 · balance_after: The reported total includes 1,373 shares of common stock the reporting person has acquired since the date of his last ownership report through the issuer's Employee Stock Purchase Plan in one or more transactions exempt pursuant to Rules 16b-3(c). Read SEC document |
| June 01, 2022 Filed Jun 1, 2022 16:31 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | PurchaseCommon Stock | 10,000 | $4.23 | $42,300.00 |
DisclosureSEC source: 0001562180-22-004627 · primarydocument.xml · nonDerivative · entry 1 Chardonnet Laurent · CIK 0001329010 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,500 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.22 to $4.23, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. Read SEC document |
| March 21, 2022 Filed Mar 22, 2022 18:01 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | GrantCommon Stock | 6,500 | $7.51 | $48,815.00 |
DisclosureSEC source: 0001209191-22-020585 · doc4.xml · nonDerivative · entry 1 Chardonnet Laurent · CIK 0001329010 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,500 Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 19:11 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | GrantEmployee Stock Option (right to buy) · Derivative | 90,000 | $0.00 Strike: $10.58 | $0.00 |
DisclosureSEC source: 0001209191-22-011037 · doc4.xml · derivative · entry 1 Chardonnet Laurent · CIK 0001329010 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2032-02-14 F1 · derivative.exercise_date: The stock option vests as to 25% of the total shares on February 15, 2023, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| December 13, 2021 Filed Dec 14, 2021 17:37 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | GrantCommon Stock | 5,000 | $12.28 | $61,400.00 |
DisclosureSEC source: 0001209191-21-069548 · doc4.xml · nonDerivative · entry 1 Chardonnet Laurent · CIK 0001329010 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.24 to $12.29, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. Read SEC document |
| November 29, 2021 Filed Dec 1, 2021 18:00 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | GrantEmployee Stock Option (Right to Buy) · Derivative | 180,000 | $0.00 Strike: $13.75 | $0.00 |
DisclosureSEC source: 0001209191-21-067324 · doc4.xml · derivative · entry 1 Chardonnet Laurent · CIK 0001329010 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,000 Underlying: Common Stock · 180,000 shares Expires 2031-11-28 F1 · derivative.exercise_date: The stock option vests as to 25% of the total shares on November 29, 2022, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| February 09, 2021 Filed Feb 11, 2021 21:28 UTC | Axcella Health Inc. AXLA · Entity 116059 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $3.40 | $0.00 |
DisclosureSEC source: 0001104659-21-020988 · tm216388-4_4seq1.xml · derivative · entry 4 Chardonnet Laurent · CIK 0001329010 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2029-12-17 F6 · kind: On December 18, 2019, the reporting person was granted an option to purchase 25,000 shares of AXLA common stock, subject to the satisfaction of certain performance criteria. On February 9, 2021, the Issuer's Board of Directors confirmed that the performance criteria had been met. F7 · derivative.exercise_date: This option shall vest and become exercisable in eight equal quarterly installments, with the first installment having vested on August 31, 2020. Read SEC document |
| February 09, 2021 Filed Feb 11, 2021 21:28 UTC | Axcella Health Inc. AXLA · Entity 116059 | GrantStock Option (Right to Buy) · Derivative | 120,000 | $0.00 Strike: $6.59 | $0.00 |
DisclosureSEC source: 0001104659-21-020988 · tm216388-4_4seq1.xml · derivative · entry 3 Chardonnet Laurent · CIK 0001329010 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2031-02-08 F5 · derivative.exercise_date: 25% of this option shall vest and become exercisable on February 9, 2022, with the remainder vesting in 12 equal quarterly installments thereafter. Read SEC document |
| February 09, 2021 Filed Feb 11, 2021 21:28 UTC | Axcella Health Inc. AXLA · Entity 116059 | GrantRestricted Stock Units · Derivative | 60,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-020988 · tm216388-4_4seq1.xml · derivative · entry 2 Chardonnet Laurent · CIK 0001329010 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of AXLA common stock. F4 · derivative.exercise_date: The restricted stock units vest as follows: 1/3 of the grant shall vest on February 9, 2023 and the remaining 2/3 of the grant shall vest on February 9, 2024. F4 · derivative.expiration_date: The restricted stock units vest as follows: 1/3 of the grant shall vest on February 9, 2023 and the remaining 2/3 of the grant shall vest on February 9, 2024. Read SEC document |
| October 30, 2020 Filed Feb 11, 2021 21:28 UTC | Axcella Health Inc. AXLA · Entity 116059 | GrantCommon Stock | 2,601 | $3.60 | $9,363.60 |
DisclosureSEC source: 0001104659-21-020988 · tm216388-4_4seq1.xml · nonDerivative · entry 1 Chardonnet Laurent · CIK 0001329010 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,266 F1 · kind: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Axcella Health Inc. Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of May 1, 2020 to October 30, 2020. F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on October 30, 2020. Read SEC document |
| January 31, 2020 Filed Jan 31, 2020 20:44 UTC | Axcella Health Inc. AXLA · Entity 116059 | PurchaseCommon Stock | 3,000 | $4.94 | $14,820.00 |
DisclosureSEC source: 0001633070-20-000004 · wf-form4_158052144753507.xml · nonDerivative · entry 1 Chardonnet Laurent · CIK 0001329010 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,665 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.90 to $4.95, inclusive. The reporting person undertakes to provide to Axcella Health Inc., any security holder of Axcella Health Inc., or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. Read SEC document |
| January 27, 2020 Filed Jan 28, 2020 18:39 UTC | Axcella Health Inc. AXLA · Entity 116059 | PurchaseCommon Stock | 352 | $4.94 | $1,738.88 |
DisclosureSEC source: 0001104659-20-007760 · a4.xml · nonDerivative · entry 2 Chardonnet Laurent · CIK 0001329010 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 665 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.94 to $4.95, inclusive. The reporting person undertakes to provide to Axcella Health Inc., any security holder of Axcella Health Inc., or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. Read SEC document |
| January 24, 2020 Filed Jan 28, 2020 18:39 UTC | Axcella Health Inc. AXLA · Entity 116059 | PurchaseCommon Stock | 313 | $4.92 | $1,539.96 |
DisclosureSEC source: 0001104659-20-007760 · a4.xml · nonDerivative · entry 1 Chardonnet Laurent · CIK 0001329010 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 313 Read SEC document |
| December 18, 2019 Filed Dec 20, 2019 20:02 UTC | Axcella Health Inc. AXLA · Entity 116059 | GrantStock Option (Right to Buy) · Derivative | 72,500 | $0.00 Strike: $3.40 | $0.00 |
DisclosureSEC source: 0001104659-19-075203 · a4.xml · derivative · entry 1 Chardonnet Laurent · CIK 0001329010 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,500 Underlying: Common Stock · 72,500 shares Expires 2029-12-18 F1 · derivative.exercise_date: 25% of this option shall vest and become exercisable on December 18, 2020, with the remainder to vest in 12 equal quarterly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.